Subscribe to Search results

"The Guardian" wrote that the most immediate concern facing the Department of Health was how to set up a mechanism and find the staff to tell donors the implications of carrying Hepatitis C antibodies.

Published on:

Dr Dow had used the new generation Abbott ELISA to retest the 69 reactive samples from the multi-centre study. Only 7 were repeatedly reactive, including the 6 which had previously tested positive under supplemental RIBA and PCR testing. The new generation test was likely to be more specific and cause fewer false positive results.

Published on:

Dr Gunson confirmed he approved the new generation Abbott Hepatitis C antibody test.

Published on:

To accommodate the slippage of the unavailability of test kits, Mr Macleod and Dr Metters postponed the introduction of routine anti-HCV screening until 1 September 1991.

Published on:

Dr Rejman wrote to Dr Gunson requesting amendments to the article to mitigate criticism relating to the timeline for introducing screening, and specifically the delay due to lack of supplementary testing.

Published on:

Dr Gunson did not believe any delay was caused by RIBA II not being available but it was due to the logistics of transferring samples from three RTCs to each of their confirmatory laboratories and the fact that 65 PCRs took a long time to complete.

Published on:

A full report of the Ortho and Abbott trial was produced by Dr Edward Follett in Glasgow.

Published on:

3,282 samples screened for ALT and anti-HBc in the NBTS three-centre study had been tested using the first-generation Chiron/Ortho ELISA test and the test was considered to be reproducible, robust and meaningful, but further study was needed.

Published on:

HCV Screening under Chiron showed effectiveness at testing when samples from North London Blood Transfusion Centre donations had tested positive when blind tested.

Published on:

ACVSB met for the first time on 4 April 1989, chaired by Dr Harris. ACVSB's role was to give advice to the UK health ministers and would focus on the major policy issues with the implementation of the policy being for others. The issue of anti-HCV testing was not covered specifically.

Published on:

Denmark, Sweden and Finland were trialling the Chiron/Ortho anti-HCV test, and several other countries were planning to do so.

Published on:

Dr Tuddenham wrote to John Canavan to support the move to evaluate the test based on detection of antibody to polypeptide synthesised by recombinant yeast clones of the HCV virus. This is because screening donor blood by such an assay could reduce the transmission rate of non-A non-B Hepatitis in single donor products and in some pooled plasma derivatives.

Published on:

Dr Lane wrote to Dr Rejman that the presence of antibody for Hepatitis C was not necessarily a marker of infectivity in HCV screening. However, Dr Gunson and the ACTTD were reporting the opposite of this, which Dr Mortimer and Professor Cash appeared to endorse.

Published on:

In a letter to Dr Rejman, Professor Arie Zuckerman stated that despite the projected costs of the screening test, the introduction of screening could not be delayed much beyond FDA approval considering the overall morbidity of chronic non-A non-B Hepatitis (including apparently autoimmune liver disease and hepatocellular carcinoma), and litigation which would be indefensible.

Published on:

A proposal for study of donations in three RTCs, Glasgow, Newcastle and North London, was agreed to be coordinated by Dr Gunson and the proposal stated that donors who tested anti-HCV positive were to be interviewed by a member of the medical staff to take medical history and arrange liver function tests.

Published on:

Dr Tedder prepared a preliminary report on the samples tested which showed how reactive the Abbott and Ortho testing were.

Published on:

The Advisory Committee on Virological Safety of Blood tabled a proposal on counselling of donors who tested anti-HCV positive and proposed to convene a meeting to consider and provide recommendations.

Published on:

An Advisory Committee on the Virological Safety of Blood discussed cases of post-transfusion hepatitis discovered through HCV screening, and second generation trials of HCV tests conducted with Ortho and Abbott.

Published on:

The first meeting of the ACTTD was held and its role was to brief the ACVSB about the decision on whether to introduce anti HCV screening.

Published on:

The ACTTD decided that Dr Gunson's paper should be used as the basis of the paper to be submitted to the department's committee and matters referred to ie counselling and flow charts would form part of the policy decisions to be taken if the Department of Health accepted the recommendation of the Committee.

Published on: